Skip to main content

Access to our Solutions

Our presence is on-the-ground: active in many low- and middle-income countries, our teams are involved in research programs and grass-roots efforts to provide an effective response to infectious risks. We make every effort to adapt to local contexts and ensure that our prices reflect the fair economic and medical value of our solutions.

Some of our partnerships:

  • Fleming Fund: In 2019, we partnered with the Fleming Fund, a UK aid investment program, to tackle antimicrobial resistance in low- and middle-income countries. Selected as a key supplier, we equip clinical and veterinary reference laboratories across 15 countries in Africa and Asia Pacific with the VITEK® MS and VITEK® 2 systems for pathogen identification and susceptibility testing, and the MYLA® software for data processing.
  • Supporting better prediction of pediatric disease severity: we support a multicentric study supervised by Oxford University to improve diagnostic testing of pediatric fevers in Southeast Asia. Equipped with our BIOFIRE® FILMARRAY® systems and BIOFIRE® Respiratory Panels (RP2), the teams will be able to test for a broader range of pathogens than those currently assessed.
  • Partnerships in the field of COVID-19:
    we, alongside 15 other healthcare companies, participate in the Bill and Melinda Gates Foundation initiative aimed at providing equitable access to COVID-19 diagnostic tests, treatments and vaccines that will help bring an end to the pandemic.
    we are joining forces with the Africa Medical Supplies Platform (AMSP) to facilitate access to diagnostic solutions to fight the COVID-19 pandemic in Africa. This partnership aims to address the supply shortages experienced by the member states of the African Union by guaranteeing effective, continuous and rapid access to bioMérieux solutions at highly competitive prices.